Raymond James Maintains Outperform Rating for AngioDynamics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has maintained its Outperform rating for AngioDynamics (NASDAQ:ANGO) but lowered its price target from $12.00 to $10.00. AngioDynamics' shares are currently trading at $6.30, down 1.25% over the last 24 hours. The new price target suggests a potential upside of 58.73% from the current share price. AngioDynamics is involved in the design, manufacture, and sale of medical devices, primarily in the United States, and generates most revenue from Endovascular Therapies.
January 09, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains Outperform rating on AngioDynamics but reduces price target from $12 to $10. Current trading price is $6.30, indicating a significant potential upside.
The maintenance of an Outperform rating by Raymond James suggests a positive outlook on AngioDynamics, which could instill investor confidence. However, the reduction in the price target may reflect a tempered but still optimistic expectation of the company's stock performance. Given the current trading price, the new target represents a substantial potential increase, which could attract investors looking for growth opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100